Daniel Mark
March 23rd, 2015
Putting PROMISE in Greater Context
Daniel Mark and Larry Husten, PHD
The PROMISE trial, which was presented and discussed in a Journal Club forum at ACC.15, prompted some interesting discussion when CardioExchange covered it as a news story on March 14. Dr. Daniel B. Mark, one of the PROMISE investigators, now sheds further light on the trial in response to questions from CardioExchange news writer Larry Husten. […]
April 9th, 2013
The TACT Investigators Respond to Questions
Gervasio Antonio Lamas, MD, Daniel Mark, Christine Goertz, DC, PhD, Robin Boineau, M.D., M.A., Kerry L. Lee, Ph.D. and Harlan M. Krumholz, MD, SM
The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.
August 6th, 2012
TAVR and the Price of Innovation
Daniel Mark, Richard A. Lange, MD, MBA and L. David Hillis, MD
In an article published in Circulation, Daniel Mark and Robert Mentz of the Duke Clinical Research Institute and University Medical Center examine the economic and policy implications of the recent validation of transcatheter aortic valve replacement (TAVR) in the PARTNER trials. CardioExchange is fortunate and pleased to present Dr. Mark’s responses to questions about his […]
NEJM Journal Watch — Recent Cardiology Articles- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise